TERT promoter mutations are emerging prognostic biomarkers in multiple cancers and are
found in highly aggressive thyroid cancer. Our aim is to investigate the prognostic value of …

Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-
derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers …

Background TERT promoter mutations are associated with adverse clinicopathological
characteristics in thyroid carcinomas and considered as a major indicator of poor outcomes …

The 2013 discovery of Telomerase reverse transcriptase (TERT) promoter mutations chr5,
1,295,228 C> T (C228T) and 1,295,250 C> T (C250T) in thyroid cancer represents an …

Background The association between telomerase reverse transcriptase (TERT) promoter
mutations and some clinical behaviors in thyroid cancer remains controversial and requires …

Simple Summary In a cohort study involving 393 patients with differentiated thyroid cancer,
TERT promoter mutations were found to act as an independent poor prognostic factor based …

Background: TERT encodes the reverse transcriptase component of telomerase, which adds
telomere repeats to chromosome ends, thus enabling cell replication. Telomerase activity is …

Context: Promoter mutations chr5: 1,295,228 C> T and chr5: 1,295,250 C> T (termed C228T
and C250T, respectively) in the gene for telomerase reverse transcriptase (TERT) have …

Telomerase reverse transcriptase (TERT) promoter mutations C228T and C250T have
recently been described in follicular cell-derived thyroid cancer (TC) in patients from North …

Background: The role of telomerase reverse transcriptase (TERT) promoter mutations in
differentiated thyroid cancer has been well established. These mutations have a significantly …